Improvement in mood does not necessarily mean that craving has ended. Zorick and colleagues’ 2010 study followed methamphetamine-dependent volunteers during monitored abstinence for up to five weeks. Average psychiatric symptoms declined substantially, while craving persisted at a reduced level later in the observation period.
Who participated, and under what conditions?
The research included 56 methamphetamine-dependent participants and 89 healthy comparisons. The methamphetamine group was not seeking treatment and lived in a research hospital; comparisons were assessed as outpatients. Participants with several major medical or psychiatric conditions were excluded.
Daily urine testing and alcohol breath testing monitored inpatient abstinence. Staff restricted drug-related cues and media, and participants had individual rooms. Those controlled conditions differ from everyday environments where people encounter stress, access to drugs and familiar cues.
The researchers did not administer a standardized methamphetamine regimen before cessation. Last-use timing combined self-report with screening information. Participants entered related research protocols lasting either two or five weeks, so the initial 56 did not all supply every five-week assessment.
What did “symptoms resolved” mean?
The paper’s abstract summarized depressive and psychotic symptoms as largely resolving within a week. The detailed results require a more qualified account. Beck Depression Inventory scores declined substantially over the first two weeks, but remained higher than comparison scores during the first three weeks.
By the end of week four, the between-group depression comparison was not statistically significant at the conventional threshold (p=0.07). That does not prove every participant was symptom-free or that the two populations were equivalent. A mean decline and the disappearance of a significant group contrast are different findings.
How did craving differ?
Craving remained elevated through the first week, fell significantly after more than two weeks relative to entry, and continued at a lower level through week five. Five weeks was the end of observation, not a demonstrated universal endpoint of craving.
At entry, craving and depression scores were not significantly correlated. Associations appeared at the first and second weeks, but not at later assessed points. The relationship between the measures therefore depended on when it was examined.
Neither a craving score nor a depression score measured the amount of methamphetamine remaining in blood. Persistent craving after monitored abstinence does not establish continued consumption, just as reduced craving does not establish absence of exposure in an unmonitored setting.
Why did the assessment method matter?
The researchers used an investigator-rated withdrawal questionnaire and self-report psychiatric scales. These did not always produce the same impression of symptom severity. The investigator-rated instrument tended to indicate lower severity than self-report measures.
Those differences could reflect what each instrument measured or how comfortable participants were disclosing symptoms. They are reasons to retain the instrument’s identity rather than combine every rating into one interchangeable “withdrawal score.”
Can the averages determine an individual recovery date?
No. The selected, medically screened, non-treatment-seeking cohort and inpatient setting limit generalization. The study did not follow participants beyond five weeks or validate its symptom pattern as a prediction rule for relapse or day-to-day functioning.
The authors discussed possible implications for relapse, but this symptom-course study did not prove that one particular day range causes the highest relapse risk. Its strongest direct evidence concerns the observed trajectories. Those trajectories show why improving psychiatric symptoms and ongoing craving can coexist, without prescribing a deadline for any individual’s recovery.
Source
Zorick T, Nestor L, Miotto K, et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. 2010;105(10):1809–1818. doi:10.1111/j.1360-0443.2010.03066.x.
Leave a Reply